Medpace/$MEDP
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Medpace
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Ticker
$MEDP
Sector
Primary listing
Employees
6,200
Headquarters
Website
Medpace Metrics
BasicAdvanced
$14B
31.32
$15.28
1.40
-
Price and volume
Market cap
$14B
Beta
1.4
52-week high
$628.92
52-week low
$250.05
Average daily volume
413K
Financial strength
Current ratio
0.736
Quick ratio
0.669
Long term debt to equity
24.755
Total debt to equity
29.811
Profitability
EBITDA (TTM)
563.059
Gross margin (TTM)
71.06%
Net profit margin (TTM)
17.83%
Operating margin (TTM)
21.14%
Effective tax rate (TTM)
16.82%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
16.40%
Return on equity (TTM)
70.23%
Valuation
Price to earnings (TTM)
31.318
Price to revenue (TTM)
5.456
Price to book
29.57
Price to tangible book (TTM)
-57.35
Price to free cash flow (TTM)
20.244
Free cash flow yield (TTM)
4.94%
Free cash flow per share (TTM)
23.638
Growth
Revenue change (TTM)
19.97%
Earnings per share change (TTM)
20.98%
3-year revenue growth (CAGR)
20.12%
10-year revenue growth (CAGR)
22.97%
3-year earnings per share growth (CAGR)
28.04%
10-year earnings per share growth (CAGR)
49.18%
What the Analysts think about Medpace
Analyst ratings (Buy, Hold, Sell) for Medpace stock.
Medpace Financial Performance
Revenues and expenses
Medpace Earnings Performance
Company profitability
Medpace News
AllArticlesVideos
Ongoing Investigation: Medpace Holdings, Inc. (MEDP) May Have Misled Shareholders - Levi & Korsinsky Investigates
Newsfile Corp·2 weeks ago
Lost Investment in Medpace Holdings, Inc. (MEDP)? Levi & Korsinsky Launches Securities Fraud Investigation
Newsfile Corp·3 weeks ago
The 'Key Negative' That Took Out Medpace's Sales, Profit Beat
Investors Business Daily·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Medpace stock?
Medpace (MEDP) has a market cap of $14B as of March 10, 2026.
What is the P/E ratio for Medpace stock?
The price to earnings (P/E) ratio for Medpace (MEDP) stock is 31.32 as of March 10, 2026.
Does Medpace stock pay dividends?
No, Medpace (MEDP) stock does not pay dividends to its shareholders as of March 10, 2026.
When is the next Medpace dividend payment date?
Medpace (MEDP) stock does not pay dividends to its shareholders.
What is the beta indicator for Medpace?
Medpace (MEDP) has a beta rating of 1.4. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.